ReviewDrugs2010
Grapefruit-drug interactions.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 147 citations in OpenAlex.
- Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics.Journal of clinical pharmacology · 2017Trial
- S-ketamine concentrations are greatly increased by grapefruit juice.European journal of clinical pharmacology · 2012Trial
- Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects.European journal of clinical pharmacology · 2012Trial
- Article
- Sesamin exhibits potential food-drug interactions through the inhibition of cytochrome P450s and human UDP-glucuronosyltransferasesRSC advances · 2026Article
- Exploring the toxic mechanism of excessive intake of naringin on drug-induced liver injury using network toxicology and experiment validation strategy.BMC pharmacology & toxicology · 2025Article
- FARFOOD: a database of potential interactions between food compounds and drugs.BioData mining · 2025Article
- Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Habitual sweet and bitter beverage consumption in relation to the risk of frailty and sarcopenia-related traits: a Mendelian randomization study.BMC geriatrics · 2025Article
- Flavonoids and Furanocoumarins Involved in Drug Interactions.Molecules (Basel, Switzerland) · 2025Review
- A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus.Clinical pharmacology and therapeutics · 2025Article
- A Narrative Review on Plant Extracts for Metabolic Syndrome: Efficacy, Safety, and Technological Advances.Nutrients · 2025Review
- Artificial Intelligence Models and Tools for the Assessment of Drug-Herb Interactions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Food-drug interactions: Modelling knowledge and attitude among healthcare professionals at the Ho Teaching Hospital.PloS one · 2025Article
- Effectiveness of Flavonoid-Rich Diet in Alleviating Symptoms of Neurodegenerative Diseases.Foods (Basel, Switzerland) · 2024Review
- DDID: a comprehensive resource for visualization and analysis of diet-drug interactions.Briefings in bioinformatics · 2024Article
- Healthcare Professionals and Undergraduate Students' Knowledge Toward Drug-Food Interactions in the Eastern Region of Saudi Arabia.Journal of multidisciplinary healthcare · 2023Article
- Flavonoid intake is associated with lower all-cause and disease-specific mortality: The National Health and Nutrition Examination Survey 2007-2010 and 2017-2018.Frontiers in nutrition · 2023Article
- Drug-food Interactions in the Era of Molecular Big Data, Machine Intelligence, and Personalized Health.Recent advances in food, nutrition & agriculture · 2022Review
- Network Analysis of the Herb-Drug Interactions of Citrus Herbs Inspired by the "Grapefruit Juice Effect".ACS omega · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Grapefruit juice and grapefruit product consumption have potential health benefits; however, their intake is also associated with interactions with certain drugs, including calcium channel blockers, immunosuppressants and antihistamines. The primary mechanism through which interactions are mediated is mechanism-based intestinal cytochrome P450 3A4 inhibition by furanocoumarins resulting in increased bioavailability of administered medications that are substrates. Grapefruit products have also been associated with interactions with P-glycoprotein (P-gp) and uptake transporters (e.g. organic anion-transporting polypeptides [OATPs]). Polyphenolic compounds such as flavonoids have been proposed as the causative agents of the P-gp and OATP interactions. The mechanisms and magnitudes of the interactions can be influenced by the concentrations of furanocoumarins and flavonoids in the grapefruit product, the volume of juice consumed, and the inherent variability of specific enzymes and transporter components in humans. It is therefore challenging to predict the extent of grapefruit product-drug interactions and to compare available in vitro and in vivo data. The clinical significance of such interactions also depends on the disposition and toxicity profile of the drug being administered. The aim of this review is to outline the mechanisms of grapefruit-drug interactions and present a comprehensive summary of those agents affected and whether they are likely to be of clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.